Clinical Trial Update: Ixabepilone in Treating Patients With Metastatic, Recurrent, or Unresectable Kidney Cancer [Phase 2]

View source ↗

Summary

This clinical trial investigates ixabepilone for metastatic, recurrent, or unresectable renal cell carcinoma in a Phase 2 study; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Ixabepilone (Ixempra) (ixabepilone)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer | Phase 2 | Status: COMPLETED